PrEP - pre-exposure prophylaxis
Aug 29, 2022 | News
For the first time, the U.S. Food and Drug Administration (FDA) has approved a long-acting injectable agent for the prevention of HIV, an alternative to daily pills for HIV prevention and an important step forward in the quest for global HIV epidemic control. ICAP at...
Mar 28, 2022 | News
From 2016 to 2021, a project designed and supported by ICAP at Columbia University delivered critical HIV health services to key and vulnerable populations in Tanzania. Known as FIKIA – “to reach” in Kiswahili – the project brought HIV testing, prevention, and care to...
Mar 25, 2022 | News
ICAP at Columbia University is supporting the introduction of an important new tool to reduce HIV transmission in Guatemala and Panama. For the first time, people at risk for HIV in these Central American countries will have access to pre-exposure prophylaxis (PrEP),...
Mar 25, 2022 | News, Stories from the Field
Since April 2021, ICAP has supported the rollout of Pre-Exposure Prophylaxis (PrEP) medication in eight key population (KP) group drop-in centers across Sierra Leone. ICAP, in collaboration with selected KP-led civil society organizations, worked to initially enroll...
Mar 21, 2022 | News
ICAP at Columbia University is testing a theory: can a smartphone app help facilitate HIV self-testing and improve PrEP adherence? Beginning in January 2021, ICAP’s Bronx Prevention Center launched “Making PrEP Smart,” a study exploring the acceptability of an app...
